Should women receive androgen replacement therapy, and if so, how?
The available clinical evidence supports efficacy of testosterone therapy for the treatment of postmenopausal women with hypoactive sexual desire disorder (HSDD) who have undergone a comprehensive clinical evaluation. Although few preparations designed to deliver an appropriate dose of testosterone for women are available, use of testosterone by women for the management of HSDD is widespread. Issues that continue to simulate debate in this therapeutic area include whether HSDD is a condition that merits pharmacotherapy, how effective is such treatment and whether testosterone therapy is safe. Hence the question, should women receive androgen replacement therapy, and if so, how?
Davis
Susan R
SR
Department of Medicine, Central & Eastern Clinical School, Monash Medical School, Alfred Hospital, Prahran, Australia. susan.davis@med.monash.edu.au
D000728:Androgens / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy
D000728:Androgens